Viracta Therapeutics Inc. (VIRX) has announced that it is currently exploring strategic alternatives with the intention of enhancing value. These potential alternatives include possibilities such as a merger, licensing agreement, sale, or other strategic transactions.
The company cautioned that there is no guarantee that this exploration will result in any specific agreements or transactions, nor can the timing of any potential outcomes be predicted.
Additionally, Viracta has decided to terminate its ongoing pivotal Phase 2 clinical trial of Nana-val, which was being conducted on patients with relapsed/refractory EBV+ lymphomas (NAVAL-1 trial). The company clarified that the decision to close the trial was made voluntarily and is not due to any newly identified safety concerns.
The material has been provided by InstaForex Company - www.instaforex.com
The company cautioned that there is no guarantee that this exploration will result in any specific agreements or transactions, nor can the timing of any potential outcomes be predicted.
Additionally, Viracta has decided to terminate its ongoing pivotal Phase 2 clinical trial of Nana-val, which was being conducted on patients with relapsed/refractory EBV+ lymphomas (NAVAL-1 trial). The company clarified that the decision to close the trial was made voluntarily and is not due to any newly identified safety concerns.
The material has been provided by InstaForex Company - www.instaforex.com